Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA.

J Pathol. 2018 May;245(1):61-73. doi: 10.1002/path.5060. Epub 2018 Mar 30.

PMID:
29464716
2.

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions.

Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B.

Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15.

3.

Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.

Collado R, Puiggros A, López-Guerrero JA, Calasanz MJ, Larráyoz MJ, Ivars D, García-Casado Z, Abella E, Orero MT, Talavera E, Oliveira AC, Hernández-Rivas JM, Hernández-Sánchez M, Luño E, Valiente A, Grau J, Portal I, Gardella S, Salgado AC, Giménez MT, Ardanaz MT, Campeny A, Hernández JJ, Álvarez S, Espinet B, Carbonell F.

Cancer Lett. 2017 Nov 28;409:42-48. doi: 10.1016/j.canlet.2017.08.041. Epub 2017 Sep 6.

PMID:
28888994
4.

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.

Rio-Machin A, Gómez-López G, Muñoz J, Garcia-Martinez F, Maiques-Diaz A, Alvarez S, Salgado RN, Shrestha M, Torres-Ruiz R, Haferlach C, Larráyoz MJ, Calasanz MJ, Fitzgibbon J, Cigudosa JC.

Leukemia. 2017 Sep;31(9):2000-2005. doi: 10.1038/leu.2017.194. Epub 2017 Jun 20. No abstract available.

5.

Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance.

Baptista MJ, Granada I, Morgades M, Calasanz MJ, Canals J, Robles De Castro D, Luño E, Ruiz-Xivillé N, Rodríguez-Hernández I, González T, Terol MJ, Valiente A, Ortuño F, Garcia-Malo MD, Piñan MÁ, Oliveira AC, Talavera M, Buño I, Batlle-López A, Moreno C, Ferra C, Solé F.

Am J Hematol. 2017 Jul;92(7):E132-E135. doi: 10.1002/ajh.24754. Epub 2017 Jun 1. No abstract available.

6.

Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.

Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJG, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI.

Cancer Cell. 2016 Nov 14;30(5):806-821. doi: 10.1016/j.ccell.2016.09.014.

7.

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.

Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R, Xochelli A, Rodríguez-Rivera M, Ortega M, Calasanz MJ, Luño E, Vargas M, Grau J, Martínez-Laperche C, Valiente A, Cervera J, Anagnostopoulos A, Gimeno E, Abella E, Stalika E, Hernández-Rivas JM, Ortuño FJ, Robles D, Ferrer A, Ivars D, González M, Bosch F, Abrisqueta P, Stamatopoulos K, Espinet B.

Oncotarget. 2016 Dec 6;7(49):80916-80924. doi: 10.18632/oncotarget.13106.

8.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

9.

Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.

Nomdedeu M, Calvo X, Pereira A, Carrió A, Solé F, Luño E, Cervera J, Vallespí T, Muñoz C, Gómez C, Arias A, Such E, Sanz G, Grau J, Insunza A, Calasanz MJ, Ardanaz MT, Hernández-Rivas JM, Azaceta G, Álvarez S, Sánchez J, Martín ML, Bargay J, Gómez V, Cervero CJ, Allegue MJ, Collado R, Campo E, Esteve J, Nomdedeu B, Costa D; Spanish Group of Myelodysplastic Syndromes.

Genes Chromosomes Cancer. 2016 Apr;55(4):322-7. doi: 10.1002/gcc.22333. Epub 2015 Dec 22.

PMID:
26690722
10.

Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.

Costa D, Muñoz C, Carrió A, Arias A, Gómez C, Solé F, Espinet B, Azaceta G, Calasanz MJ, Nomdedeu M, Calvo X, Campo E, Nomdedeu B.

Acta Haematol. 2016;135(2):94-100. doi: 10.1159/000439161. Epub 2015 Oct 28.

PMID:
26509426
11.

Use of human pharyngeal and palatine tonsils as a reservoir for the analysis of B-cell ontogeny in 10 paired samples.

Pascual M, Alignani D, Vilas-Zornoza A, Delgado JA, Vázquez I, Malumbres R, Rodriguez I, Barriuso R, Calasanz MJ, Paiva B, Agirre X, Prósper F, Cervera-Paz FJ.

Clin Otolaryngol. 2016 Oct;41(5):606-11. doi: 10.1111/coa.12540. Epub 2016 Feb 8. No abstract available.

PMID:
26384863
12.

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).

Bello E, Pellagatti A, Shaw J, Mecucci C, Kušec R, Killick S, Giagounidis A, Raynaud S, Calasanz MJ, Fenaux P, Boultwood J.

Br J Haematol. 2015 Oct;171(2):210-214. doi: 10.1111/bjh.13563. Epub 2015 Jun 18.

13.

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Pellagatti A, Roy S, Di Genua C, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J.

Leukemia. 2016 Jan;30(1):247-50. doi: 10.1038/leu.2015.129. Epub 2015 May 20. No abstract available.

14.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF.

Blood Cancer J. 2015 Mar 13;5:e291. doi: 10.1038/bcj.2015.11.

15.

Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.

Adema V, Larráyoz MJ, Calasanz MJ, Palomo L, Patiño-García A, Agirre X, Hernández-Rivas JM, Lumbreras E, Buño I, Martinez-Laperche C, Mallo M, García O, Álvarez S, Blazquez B, Cervera J, Luño E, Valiente A, Vallespí MT, Arenillas L, Collado R, Pérez-Oteyza J, Solé F.

Br J Haematol. 2015 Oct;171(1):137-41. doi: 10.1111/bjh.13355. Epub 2015 Feb 25. No abstract available.

PMID:
25716545
16.

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.

Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Datta A, Russiñol N, Queirós AC, Beekman R, Rodríguez-Madoz JR, San José-Enériz E, Fang F, Gutiérrez NC, García-Verdugo JM, Robson MI, Schirmer EC, Guruceaga E, Martens JH, Gut M, Calasanz MJ, Flicek P, Siebert R, Campo E, Miguel JF, Melnick A, Stunnenberg HG, Gut IG, Prosper F, Martín-Subero JI.

Genome Res. 2015 Apr;25(4):478-87. doi: 10.1101/gr.180240.114. Epub 2015 Feb 2.

17.

CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.

Barragán E, Chillón MC, Castelló-Cros R, Marcotegui N, Prieto MI, Hoyos M, Pippa R, Llop M, Etxabe A, Cervera J, Rodríguez G, Buño I, Rifón J, Sierra J, González M, Calasanz MJ, Sanz MA, Odero MD.

Haematologica. 2015 May;100(5):e183-5. doi: 10.3324/haematol.2014.118117. Epub 2015 Jan 30. No abstract available.

18.

Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.

Puiggros A, Venturas M, Salido M, Blanco G, Fernandez-Rodriguez C, Collado R, Valiente A, Ruiz-Xivillé N, Carrió A, Ortuño FJ, Luño E, Calasanz MJ, Ardanaz MT, Piñán MÁ, Talavera E, González MT, Ortega M, Marugán I, Ferrer A, Gimeno E, Bellosillo B, Delgado J, Hernández JÁ, Hernández-Rivas JM, Espinet B; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH); Grupo Español de Leucemia Linfática Crónica (GELLC).

Genes Chromosomes Cancer. 2014 Sep;53(9):788-97. doi: 10.1002/gcc.22188. Epub 2014 Jun 10.

PMID:
24915757
19.

Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia.

Saumell S, Florensa L, Rodríguez-Rivera M, Pedro C, Hernández-Rivas JM, Lumbreras E, Abáigar M, Collado R, Ivars D, Carbonell F, Marugán I, Tormo M, Botia M, Piñan MÁ, Ancín I, González T, Varela ND, Grau J, Granada I, Ruiz N, Martín ML, Fernández-Guijarro M, Duarte JJ, Calasanz MJ, Larrayoz MJ, Solé F.

Leuk Lymphoma. 2015 Jan;56(1):242-3. doi: 10.3109/10428194.2014.914197. Epub 2014 Jun 25. No abstract available.

PMID:
24724779
20.

Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.

Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, Kwon M, Court F, Siebert R, Monk D.

J Hematol Oncol. 2014 Jan 9;7:4. doi: 10.1186/1756-8722-7-4.

21.

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.

Pellagatti A, Fernandez-Mercado M, Di Genua C, Larrayoz MJ, Killick S, Dolatshad H, Burns A, Calasanz MJ, Schuh A, Boultwood J.

Leukemia. 2014 May;28(5):1148-51. doi: 10.1038/leu.2013.381. Epub 2013 Dec 24. No abstract available.

PMID:
24365791
22.

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Di Croce L, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18250-5. doi: 10.1073/pnas.1314608110. Epub 2013 Oct 21.

23.

Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.

Menezes J, Acquadro F, Wiseman M, Gómez-López G, Salgado RN, Talavera-Casañas JG, Buño I, Cervera JV, Montes-Moreno S, Hernández-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, Álvarez S, Cigudosa JC.

Leukemia. 2014 Apr;28(4):823-9. doi: 10.1038/leu.2013.283. Epub 2013 Sep 27.

PMID:
24072100
24.

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P, Burns A, Schuh A, Calasanz MJ, Cross NC, Boultwood J.

Br J Haematol. 2013 Oct;163(2):235-9. doi: 10.1111/bjh.12491. Epub 2013 Jul 24.

PMID:
23889083
25.

Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion.

Puiggros A, Delgado J, Rodriguez-Vicente A, Collado R, Aventín A, Luño E, Grau J, Hernandez JÁ, Marugán I, Ardanaz M, González T, Valiente A, Osma M, Calasanz MJ, Sanzo C, Carrió A, Ortega M, Santacruz R, Abrisqueta P, Abella E, Bosch F, Carbonell F, Solé F, Hernández JM, Espinet B; Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC).

Br J Haematol. 2013 Oct;163(1):47-54. doi: 10.1111/bjh.12479. Epub 2013 Jul 19.

PMID:
23869550
26.

Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.

Cristóbal I, Cirauqui C, Castello-Cros R, Garcia-Orti L, Calasanz MJ, Odero MD.

Haematologica. 2013 Sep;98(9):e103-4. doi: 10.3324/haematol.2013.084731. Epub 2013 Jun 28. No abstract available.

27.

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.

Pérez C, Pascual M, Martín-Subero JI, Bellosillo B, Segura V, Delabesse E, Álvarez S, Larrayoz MJ, Rifón J, Cigudosa JC, Besses C, Calasanz MJ, Cross NC, Prósper F, Agirre X.

Haematologica. 2013 Sep;98(9):1414-20. doi: 10.3324/haematol.2013.084160. Epub 2013 May 28.

28.

Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.

Costa D, Muñoz C, Carrió A, Nomdedeu M, Calvo X, Solé F, Luño E, Cervera J, Vallespí T, Berneaga D, Gómez C, Arias A, Such E, Sanz G, Grau J, Insunza A, Calasanz MJ, Ardañaz MT, Hernández JM, Azaceta G, Álvarez S, Sánchez J, Martín ML, Bargay J, Gómez V, Cervero CJ, Allegue MJ, Collado R, Campo E, Nomdedeu B; Spanish Group of Myelodysplastic Syndromes (GESMD).

Genes Chromosomes Cancer. 2013 Aug;52(8):753-63. doi: 10.1002/gcc.22071. Epub 2013 May 19.

PMID:
23686965
29.

Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.

Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, Arenillas L, Valcarcel D, Vallespí T, Costa D, Nomdedeu B, Jimenez MJ, Granada I, Grau J, Ardanaz MT, de la Serna J, Carbonell F, Cervera J, Sierra A, Luño E, Cervero CJ, Falantes J, Calasanz MJ, González-Porrás JR, Bailén A, Amigo ML, Sanz G, Solé F.

Leuk Res. 2013 Jul;37(7):769-76. doi: 10.1016/j.leukres.2013.04.010. Epub 2013 Apr 29.

PMID:
23639672
30.

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F.

Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.

PMID:
23614682
31.

Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.

Rio-Machin A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martínez J, Fonseca R, Cigudosa JC.

Leukemia. 2013 Apr;27(4):925-31. doi: 10.1038/leu.2012.302. Epub 2012 Oct 22.

PMID:
23174883
32.

Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia.

García-Ortí L, Cristóbal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ, Castello-Cros R, Odero MD.

PLoS One. 2012;7(10):e47717. doi: 10.1371/journal.pone.0047717. Epub 2012 Oct 15.

33.

Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A, Stamatopoulos K, Beà S, Campo E.

Cancer Res. 2012 Oct 15;72(20):5307-16. doi: 10.1158/0008-5472.CAN-12-1615. Epub 2012 Aug 20.

34.

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J.

PLoS One. 2012;7(8):e42334. doi: 10.1371/journal.pone.0042334. Epub 2012 Aug 9.

35.

High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.

Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, Agirre X, Catarino S, Arteta D, Osaba L, Mollejo M, Hernandez-Rivas JM, Calasanz MJ, Daibata M, Dyer MJ, Prosper F, Vizcarra E, Piris MÁ, Oscier D, Martinez-Climent JA.

Br J Haematol. 2012 Sep;158(6):712-26. doi: 10.1111/j.1365-2141.2012.09226.x. Epub 2012 Jul 23.

PMID:
22816737
36.

CBL RING finger deletions are common in core-binding factor acute myeloid leukemias.

Aranaz P, Miguéliz I, Hurtado C, Erquiaga I, Larráyoz MJ, Calasanz MJ, García-Delgado M, Novo FJ, Vizmanos JL.

Leuk Lymphoma. 2013 Feb;54(2):428-31. doi: 10.3109/10428194.2012.709629. Epub 2012 Aug 13. No abstract available.

PMID:
22799433
37.

Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.

Maicas M, Vázquez I, Vicente C, García-Sánchez MA, Marcotegui N, Urquiza L, Calasanz MJ, Odero MD.

Oncogene. 2013 Apr 18;32(16):2069-78. doi: 10.1038/onc.2012.222. Epub 2012 Jun 11.

PMID:
22689058
38.

TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.

Pérez C, Martínez-Calle N, Martín-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, Boultwood J, Wainscoat JS, Cruz Cigudosa J, Calasanz MJ, Cross NC, Prósper F, Agirre X.

PLoS One. 2012;7(2):e31605. doi: 10.1371/journal.pone.0031605. Epub 2012 Feb 6.

39.

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.

Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A, José-Eneriz ES, Miranda E, Martín-Subero JI, Garate L, Blanco-Prieto MJ, García de Jalón JA, Rio P, Rifón J, Cigudosa JC, Martinez-Climent JA, Román-Gómez J, Calasanz MJ, Ribera JM, Prósper F.

Leukemia. 2012 Jul;26(7):1517-26. doi: 10.1038/leu.2012.31. Epub 2012 Feb 6.

PMID:
22307227
40.

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S.

Leukemia. 2012 Jun;26(6):1329-37. doi: 10.1038/leu.2011.376. Epub 2012 Jan 13.

PMID:
22289984
41.

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.

Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ, Odero MD.

Haematologica. 2012 Apr;97(4):543-50. doi: 10.3324/haematol.2011.050542. Epub 2011 Dec 1.

42.

Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities.

Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, González M, Calasanz MJ, Lahortiga I, Odero MD.

Leukemia. 2012 Mar;26(3):550-4. doi: 10.1038/leu.2011.235. Epub 2011 Sep 9. No abstract available.

PMID:
21904383
43.

Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family.

Rodriguez-Otero P, Román-Gómez J, Vilas-Zornoza A, José-Eneriz ES, Martín-Palanco V, Rifón J, Torres A, Calasanz MJ, Agirre X, Prosper F.

Br J Haematol. 2011 Oct;155(1):73-83. doi: 10.1111/j.1365-2141.2011.08812.x. Epub 2011 Aug 2.

PMID:
21810092
44.

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gómez-Casares MT, Hernández-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD.

Haematologica. 2011 Oct;96(10):1448-56. doi: 10.3324/haematol.2011.040535. Epub 2011 Jul 12.

45.

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.

Beltran E, Fresquet V, Martinez-Useros J, Richter-Larrea JA, Sagardoy A, Sesma I, Almada LL, Montes-Moreno S, Siebert R, Gesk S, Calasanz MJ, Malumbres R, Rieger M, Prosper F, Lossos IS, Piris MA, Fernandez-Zapico ME, Martinez-Climent JA.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12461-6. doi: 10.1073/pnas.1018941108. Epub 2011 Jul 11.

46.

Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.

Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B, Martín-Guerrero I, Agirre X, Lujambio A, Richter J, Xargay-Torrent S, Bea S, Hernandez L, Enjuanes A, Calasanz MJ, Rosenwald A, Ott G, Roman-Gomez J, Prosper F, Esteller M, Jares P, Siebert R, Campo E, Martín-Subero JI, Amador V.

PLoS One. 2011;6(6):e21382. doi: 10.1371/journal.pone.0021382. Epub 2011 Jun 27.

47.

Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells.

Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F, Corominas M, Graña O, Ciudad L, Agirre X, Pisano DG, Valencia A, Roman-Gomez J, Calasanz MJ, Prosper F, Esteller M, Gonzalez-Sarmiento R, Ballestar E.

Mol Cancer Res. 2011 Aug;9(8):1139-51. doi: 10.1158/1541-7786.MCR-10-0515. Epub 2011 Jul 7. Erratum in: Mol Cancer Res. 2011 Oct;9(10):1429-32.

48.

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17.

49.

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.

Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-Palanco V, Prosper F, Lossos IS, Martinez-Climent JA.

Haematologica. 2011 Jul;96(7):980-6. doi: 10.3324/haematol.2011.040568. Epub 2011 Apr 1.

50.

NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

Ammatuna E, Panetta P, Agirre X, Ottone T, Lavorgna S, Calasanz MJ, Lo-Coco F.

Haematologica. 2011 May;96(5):784-5. doi: 10.3324/haematol.2010.038620. Epub 2011 Mar 10. No abstract available.

Supplemental Content

Loading ...
Support Center